Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538–e548. https://doi.org/10.1016/S1470-2045(14)70442-5

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71:7–33. https://doi.org/10.3322/caac.21654

Article  PubMed  Google Scholar 

Lapietra G, Fazio F, Petrucci MT (2022) Race for the cure: from the oldest to the newest monoclonal antibodies for multiple myeloma treatment. Biomolecules 12:1146. https://doi.org/10.3390/biom12081146

Article  CAS  PubMed  PubMed Central  Google Scholar 

US Food and Drug Administration (2024) Full prescribing information DARZALEX®. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761036s050lbl.pdf. Accessed 31 Oct 2024

US Food and Drug Administration (2024) Full prescribing information SARCLISA®. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761113s012lbl.pdf. Accessed 31 Oct 2024

US Food and Drug Administration (2022) Full prescribing information EMPLICITI®. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761035s015lbl.pdf. Accessed 31 Oct 2024

US Food and Drug Administration (2020) Full prescribing information BLENREP®. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf. Accessed 31 Oct 2024

US Food and Drug Administration (2024) Full prescribing information TECVAYLI®. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761291s008lbl.pdf. Accessed 31 Oct 2024

US Food and Drug Administration (2023) Full prescribing information ELREXFIO®. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761345Orig1s000lbl.pdf. Accessed 31 Oct 2024

US Food and Drug Administration (2023) Full prescribing information TALVEY®. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761342s000lbl.pdf. Accessed 31 Oct 2024

Cicala G, Russo G, Santoro V et al (2024) Neuropsychiatric adverse events with monoclonal antibodies approved for multiple myeloma: an analysis from the FDA adverse event reporting system. Pharmaceuticals (Basel) 17:1266. https://doi.org/10.3390/PH17101266

Article  CAS  PubMed  Google Scholar 

Lyon AR, López-Fernánde T, Couch LS et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43:4229–4361. https://doi.org/10.1093/EURHEARTJ/EHAC244

Article  PubMed  Google Scholar 

Zhai Y, Ye X, Hu F et al (2021) Cardiovascular toxicity of carfilzomib: the real-world evidence based on the adverse event reporting system database of the FDA, the United States. Front Cardiovasc Med 8:735466. https://doi.org/10.3389/FCVM.2021.735466

Al-Yafeai Z, Ghoweba M, Ananthaneni A et al (2023) Cardiovascular complications of modern multiple myeloma therapy: a pharmacovigilance study. Br J Clin Pharmacol 89:641–648. https://doi.org/10.1111/bcp.15499

Article  CAS  PubMed  Google Scholar 

Jiang T, Su H, Li Y et al (2022) Post-marketing safety of immunomodulatory drugs in multiple myeloma: a pharmacovigilance investigation based on the FDA adverse event reporting system. Front Pharmacol 13:989032. https://doi.org/10.3389/FPHAR.2022.989032

Fujiwara M, Uchida M, Endo M et al (2023) Cardiac adverse events associated with multiple myeloma patients treated with proteasome inhibitors. Oncology 101:343–348. https://doi.org/10.1159/000529341

Article  CAS  PubMed  Google Scholar 

Peng Y, Zhou Y, Shu K et al (2024) Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS. Front Pharmacol 15:1396378. https://doi.org/10.3389/FPHAR.2024.1396378/BIBTEX

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borrelli EP, McGladrigan CG (2021) Differences in safety profiles of newly approved medications for multiple myeloma in real-world settings versus randomized controlled trials. J Oncol Pharm Pract 27:887–896. https://doi.org/10.1177/1078155220941937

Article  CAS  PubMed  Google Scholar 

Chen M, Zhao L, Yao F, Yang XD (2022) Severe lung injury induced by CD38 monoclonal antibody daratumumab and bortezomib-containing regimen in a patient with preexisting interstitial lung disease: a case report and literature review. J Clin Pharm Ther 47:2387–2392. https://doi.org/10.1111/jcpt.13819

Article  CAS  PubMed  Google Scholar 

Barbieri MA, Russo G, Sorbara EE et al (2023) Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA adverse event reporting system. Front Oncol 13:1268672. https://doi.org/10.3389/fonc.2023.1268672

Harpaz R, DuMouchel W, LePendu P et al (2013) Performance of pharmacovigilance signal-detection algorithms for the FDA Adverse Event Reporting System. Clin Pharmacol Ther 93:539–546. https://doi.org/10.1038/clpt.2013.24

Article  CAS  PubMed  Google Scholar 

Fusaroli M, Salvo F, Begaud B et al (2024) The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): Development and Statement. Drug Saf 47:575–584. https://doi.org/10.1007/S40264-024-01421-9

Article  PubMed  PubMed Central  Google Scholar 

Howlader N, Noone A, Krapcho M et al (2020) SEER cancer statistics review, 1975–2017, National Cancer Institute. Bethesda, MD. In: https://seer.cancer.gov/Csr/1975_2017/. Accessed 30 Jan 2023

Gao Z, Chen Z, Sun A, Deng X (2019) Gender differences in cardiovascular disease. Med Nov Technol Devices 4:100025. https://doi.org/10.1016/j.medntd.2019.100025

Article  Google Scholar 

Hari P, Romanus D, Luptakova K et al (2018) The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies. J Geriatr Oncol 9:138–144. https://doi.org/10.1016/j.jgo.2017.09.007

Article  PubMed  Google Scholar 

Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23:2900–2902. https://doi.org/10.1200/JCO.2005.05.827

Article  CAS  PubMed  Google Scholar 

Peymani P, Tabrizi R, Afifi S et al (2016) Knowledge, attitude and practice of General Practitioners towards adverse drug reaction reporting in South of Iran, Shiraz (Pharmacoepidemiology report). Int J Risk Safety Med 28:25–31. https://doi.org/10.3233/JRS-160670

Article  Google Scholar 

Yun X, Zhou Y, Wu D et al (2024) A real-world pharmacovigilance study of FDA adverse event reporting system events for daratumumab. Expert Opin Drug Saf 23:581–591. https://doi.org/10.1080/14740338.2024.2328321

Article  CAS  PubMed  Google Scholar 

Plummer C, Driessen C, Szabo Z, Mateos M-V (2019) Management of cardiovascular risk in patients with multiple myeloma. Blood Cancer J 9:26. https://doi.org/10.1038/s41408-019-0183-y

Article  PubMed  PubMed Central  Google Scholar 

Al-Kindi SG, Oliveira GH (2016) Prevalence of preexisting cardiovascular disease in patients with different types of cancer. Mayo Clin Proc 91:81–83. https://doi.org/10.1016/j.mayocp.2015.09.009

Article  PubMed  Google Scholar 

El-Cheikh J, Moukalled N, Malard F et al (2023) Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies. Blood Cancer J 13:83. https://doi.org/10.1038/s41408-023-00849-z

Article  PubMed  PubMed Central  Google Scholar 

Morfino P, Aimo A, Castiglione V et al (2023) Cardiovascular toxicity from therapies for light chain amyloidosis. Front Cardiovasc Med 10:1212983. https://doi.org/10.3389/FCVM.2023.1212983/BIBTEX

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sayed A, Munir M, Ghazi SM et al (2024) Cardiovascular toxicities associated with bispecific T-cell engager therapy. J Immunother Cancer 12:e008518. https://doi.org/10.1136/jitc-2023-008518

Article  PubMed  PubMed Central  Google Scholar 

Baik AH, Oluwole OO, Johnson DB et al (2021) Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. Circ Res 128:1780–1801. https://doi.org/10.1161/CIRCRESAHA.120.315894

Article  CAS  PubMed  PubMed Central  Google Scholar 

Falk RH, Alexander KM, Liao R, Dorbala S (2016) AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol 68:1323–1341. https://doi.org/10.1016/j.jacc.2016.06.053

Article  PubMed  Google Scholar 

Gilotra NA, Chow GV, Cingolani OH (2013) Cardiac amyloidosis presenting with prolonged QT interval and recurrent polymorphic ventricular tachycardia. Tex Heart Inst J 40:193–195

PubMed  PubMed Central  Google Scholar 

Kastritis E, Palladini G, Minnema MC et al (2021) Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 385:46–58. https://doi.org/10.1056/NEJMoa2028631

Article  CAS